Eli Lilly Likely To Launch Weight Loss & Anti-Diabetes Drug In India: Is It Safe To Consume?
(MENAFN- Live Mint) US-based Pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from the company.
Eli Lilly sells Tirzepetide under the name of Mounjaro, a prescription-based medication that has to be injected once a week. It helps to manage obesity and diabetes, which is a serious disease and not only a cosmetic issue, according to the company.
Also Read | Budget 2025: New tax
Regime vs. old tax regime – which one to opt for Here's all you need to know about Mounjaro
Price
The company has not finalised the price of the drug .
We haven't yet finalised the pricing strategy for the Tirzapedite, but our pricing will reflect the medicine's efficacy and the fact that it improves overall health and reduces the economic burden attached to diabetes and obesity," Rachel Batterham, senior vice president of international medical affairs at Eli Lilly told News18.
Safety
While speaking about the safety and efficiency of the drug, Batterham said,“Tirzepetide (Mounjaro) is already been given to millions of people globally. It has shown a lot of impact on improving health and obesity-related complications," and takes safety“very seriously and in all our clinical trials we are looking at safety."
Also Read | How much tax will you save in the new regime? Here's the math Consequences
Several reports have raised concerns over the use of Mounjaro.
According to a Healthline report, consumption of Mounjaro may have several consequences, such as vomiting, diarrhea, decreased appetite, indigestion, abdominal pain and other rare side effects, include risk of thyroid cancer, acute pancreatitis, hypoglycemia, acute gallbladder disease, and allergic reaction.
Who should not consume?
Tirzepatide should not be consumed by pregnant women and people with rare conditions.
MENAFN03022025007365015876ID1109161712
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.